omniture

China Medical Technologies Receives SFDA Approval for its SPR-based HPV-DNA Chip

2010-06-09 18:57 1272


BEIJING, June 9 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its SPR-based HPV-DNA chip (the "HPV Chip") from the State Food and Drug Administration of China (the "SFDA").

Human papillomavirus ("HPV") is a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer. Over 100 HPV subtypes have been identified, in which 16 high risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 81) may lead to the development of cervical cancer and 8 low risk HPV subtypes (6, 11, 40, 42, 43, 44, 54, 70) may lead to genital warts. The HPV Chip can detect the high risk genotypes as well as the low risk genotypes by placing a patient's sample on one chip and processing the chip by the Company's

fully-automated SPR analyzer. The HPV Chip can also distinguish multiple HPV infection as well as determine the viral load which are all important for physicians to recommend treatment for patients.

According to the World Health Organization, China has a population of about 500 million women ages 15 years and older who are under the risk of cervical cancer. According to the Ministry of Health in China, approximately 70 million gynecological check-ups were conducted in 2008.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com .

For more information, please contact:

Winnie Yam

Tel: +852-2511-9808

Email: IR@chinameditech.com

Source: China Medical Technologies, Inc.
Related Stocks:
NASDAQ:CMED
collection